KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).

Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2021
This article has no abstract
Epistemonikos ID: f5455195886965690bc40d0fa5843c4bbfa9ad84
First added on: Feb 13, 2025